Expression of C-Erb B-2/Her-2 in Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy and Autologous Blood Stem Cell Support

Bewick, Mary A.; Chadderton, Tony; Conlon, Michael; Lafrenie, Robert M.; Glück, Stefan

doi:10.1007/978-1-4615-4797-6_12

Cited by 1 publication

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two previously published studies from this lab showed that HER-2 status was an independent prognostic factor for patients with metastatic breast cancer undergoing HDCT with ASCT (23)(24)(25). In the current study, survival analysis for the combined group of 94 patients from these previous two studies showed that HER-2 remained an independent prognostic factor.…”

Section: Discussionmentioning

confidence: 38%

“…However, there were no significant differences in PFS and OS between responding patients (CR 1 PR) and nonresponding patients (PD 1 SD). Furthermore, there was no significant association between responders (CR 1 PR) or nonresponders (SD 1 PD) and over-expression of sFas or HER-2 (results from two previous studies) ( [23][24][25], although within the responding group there was a smaller proportion of patients who over-expressed sFas or HER-2. Within the subgroup of responding patients (CR 1 PR, n 5 75), over-expression of either sFas or HER-2 was associated with significantly decreased PFS (sFas, p 5 0.03; HER-2, p 5 0.0001) and OS (sFas, p 5 0.01; HER-2, p 5 0.0003).…”

Section: Sfas Expression and Clinical And Pathological Characteristicsmentioning

confidence: 63%

“…Information on age, previous hormone treatment, and metastatic sites was available for this group of patients. The HER-2 status for this group of patients was available from the results of previously published studies (23)(24)(25). Information on hormone receptor status was available for a reduced subset of this patient group (n 5 80 for estrogen receptor and n 5 77 for progesterone receptor).…”

Section: Patient Populationmentioning

confidence: 99%

See 2 more Smart Citations

Soluble Fas (CD95) Is a Prognostic Factor in Patients with Metastatic Breast Cancer Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Bewick

Conlon

Parissenti

et al. 2001

Journal of Hematotherapy & Stem Cell Research

Self Cite

View full text Add to dashboard Cite

The Fas/Fas ligand (FasL) system plays an important role in cellular apoptosis and is involved in cancer cell death induced by the immune system and anticancer drugs. Increased serum levels of soluble Fas (sFas) are associated with a number of different disease states and with tumor progression and metastasis in patients. In this study, we examined the plasma levels of sFas in 94 women with metastatic breast cancer undergoing high-dose chemotherapy (HDCT) treatment with autologous stem cell transplantation (ASCT) using a quantitative enzyme-linked immunosorbent assay (ELISA) method. Thirty-one patients (31/94, 33%) had plasma sFas levels greater than the optimum cut point of 1.90 ng/ml (median 2.47, range 1.98-13.54 ng/ml) and were designated as sFas positive. Sixty-three patients (63/94, 67%) had sFas levels below 1.90 ng/ml (median 1.14, range 0.47-1.89 ng/ml). In univariate analysis, patients with sFas-positive status, HER-2 overexpression, and the presence of liver metastases had a significantly shorter time to disease progression (PFS) and significantly decreased overall survival (OS). Multivariable analysis (Cox proportional hazards model) for PFS determined that sFas status significantly predicted disease progression (p = 0.004) with an adjusted hazard ratio (HR) of 2.0 (95% CI, 1.3-3.3). HER-2 status and liver metastases were also significant independent predictors of disease progression (p < 0.001) for both. sFas level was also an independent prognostic factor for OS with an adjusted HR of 2.0 (p = 0.006; 95% CI, 1.2-3.4). HER-2 status and liver metastases also remained highly significant independent prognostic factors for OS (HER-2: p < 0.001, HR 2.3, and liver metastases: p = 0.001, HR 2.7). In conclusion, these results suggest that plasma levels of sFas may be a valuable clinical prognostic factor in predicting outcome (PFS and OS) for patients with metastatic breast cancer undergoing HDCT with ASCT.

show abstract

Section: Discussionmentioning

confidence: 38%

Section: Sfas Expression and Clinical And Pathological Characteristicsmentioning

confidence: 63%